TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07725562: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Clinical Trial to Evaluate the Efficacy and Safety of Oral VG081821AC Tablets Monotherapy (Without Concomitant Levodopa) in Patients With Early to Mid

Sponsor: Zhejiang Vimgreen Pharmaceuticals, Ltd. · Phase: PHASE2/PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 152 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,147,520

Rescue Site Savings

+$9,987,896

Unlock Full NCT07725562 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07725562 Rescue Dossier →